Aspira Women's Health Inc.

As of June 30, 2026, Aspira Women's Health Inc. carries a market capitalization of 18.90M, placing it among publicly traded companies globally. Its enterprise value stands at 21.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aspira Women's Health Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Aspira Women's Health Inc. has 46.63M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.99, and the price-to-book ratio stands at -2.60.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 21.52M versus a market cap of 18.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aspira Women's Health Inc. maintains a current ratio of 0.52, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -42.79, indicating conservative leverage, while an interest coverage ratio of -14.26 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -213.58, reflecting losses generated across the asset base. The company generates approximately 189,911.11 in revenue per employee across its workforce of 45.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.98 indicates how many times Aspira Women's Health Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Aspira Women's Health Inc.'s stock has declined approximately 54.36% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.38.

Over the twelve months ended June 30, 2026, Aspira Women's Health Inc. generated 8.55M in revenue and converted that into -10.00M in net income, yielding earnings per share of -0.24. EBITDA reached -6.73M, while operating income came in at -6.90M.

As of June 30, 2026, Aspira Women's Health Inc. holds 477,000.00 in cash and equivalents against 3.11M in total debt, resulting in a net debt position of 1.23M. Total book value stands at -7.26M, with working capital of -2.54M providing operational flexibility.

Aspira Women's Health Inc. produced -4.56M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -16,000.00 in capital expenditures, free cash flow totaled -4.58M - equivalent to -0.11 per share.

Over the twelve months ended June 30, 2026, Aspira Women's Health Inc. posted a gross margin of 58.78, reflecting its pricing power and cost economics. The operating margin of -80.75 and net profit margin of -117.07 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -26.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.41, meaning Aspira Women's Health Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Aspira Women's Health Inc.'s most recent stock split took place on May 12, 2023 with a 15:1 split ratio.

As of June 30, 2026, Aspira Women's Health Inc. has an Altman Z-Score of -185.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.